Non-Conventional Yeast Species for Recombinant Protein and Metabolite Production

Diem, Do Thi Hoang; Vandermies, Marie; Fickers, Patrick; Theron, Chrispian W.

doi:10.1016/b978-0-12-809633-8.20885-6

Cited by 5 publications

(2 citation statements)

References 281 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, studies in both P. pastoris 20 and Y. lipolytica 21 demonstrated reasonable expression leeway between different integration loci in both strains. Nevertheless, both of the integration targets used in this study, the LEU2 locus (where the zeta element docking platform has been introduced) in Y. lipolytica and the HIS4 locus in P. pastoris, are among the most commonly used integration targets for the respective species 22 .…”

Section: Resultsmentioning

confidence: 99%

Comprehensive comparison of Yarrowia lipolytica and Pichia pastoris for production of Candida antarctica lipase B

Theron

Vandermies

Telek

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

The large-scale production of recombinant proteins (rProt) is becoming increasingly economically important. Among the different hosts used for rProt production, yeasts are gaining popularity. The socalled non-conventional yeasts, such as the methylotrophic Pichia pastoris and the dimorphic Yarrowia lipolytica, are popular choices due to their favorable characteristics and well-established expression systems. Nevertheless, a direct comparison of the two systems for rProt production and secretion was lacking. This study therefore aimed to directly compare Y. lipolytica and P. pastoris for the production and secretion of lipase CalB in bioreactor. Y. lipolytica produced more than double the biomass and more than 5-fold higher extracellular lipase than P. pastoris. Furthermore, maximal CalB production levels were reached by Y. lipolytica in half the cultivation time required for maximal production by P. pastoris. Conversely, P. pastoris was found to express 7-fold higher levels of CalB mRNA. Secreted enhanced green fluorescent protein -in isolation and fused to CalB-and protease inhibitor MG-132 were used in P. pastoris to further investigate the reasons behind such discrepancy. The most likely explanation was ultimately found to be protein degradation by endoplasmic reticulum-associated protein degradation preceding successful secretion. This study highlighted the multifaceted nature of rProt production, prompting a global outlook for selection of rProt production systems.The production of recombinant proteins (rProt) at industrial scale is of increasing economic importance. Among the different microbial chassis that have been developed for that purpose, yeasts are emerging as the preferred option for the production of recombinant enzymes and therapeutic proteins. The main advantage of yeasts over bacterial systems such as Escherichia coli is the possibility to obtain post-translational modified proteins in the culture supernatant at a gram per liter scale. Historically, Saccharomyces cerevisiae has been used as the reference eukaryotic chassis, however it suffers several drawbacks such as low protein productivity, overflow metabolism and hyperglycosylation of rProt. Moreover, it is less metabolically adapted to catabolize raw carbon and nitrogen sources, which are nowadays increasingly considered as feedstocks in bioprocesses, with the intention of reducing the process costs. Currently, non-conventional yeasts such as Pichia pastoris and Yarrowia lipolytica are considered as realistic alternatives to S. cerevisiae for rProt synthesis. Both species combine the advantages of growth at high cell density and production and secretion of rProt at high yields, with low nutritional requirements, thus allowing growth on raw materials or industrial by-products 1,2 .In most cases, the processes developed for rProt production are two-step systems involving a first phase of biomass generation under repressive or non-inducing conditions, followed by an induction phase during which rProt are synthetized and secreted into the cult...

show abstract

Section: Resultsmentioning

confidence: 99%

Comprehensive comparison of Yarrowia lipolytica and Pichia pastoris for production of Candida antarctica lipase B

Theron

Vandermies

Telek

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…RNA molecules expressed from U6 or H1 Type 3 Pol III promoters then mediate sequence-specific RNAi-based gene inhibition. ( Ill and Chiou, 2005 ; Marín-garcía and MarÍN-GarcÍA, 2007 ; Do et al, 2019 ) A list of siRNA therapeutics can be seen at Table 1 .…”

Section: Rna Therapeuticsmentioning

confidence: 99%

RNA Therapeutics - Research and Clinical Advancements

Feng¹,

Patil

Zhao

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

RNA therapeutics involve the use of coding RNA such as mRNA as well as non-coding RNAs such as small interfering RNAs (siRNA), antisense oligonucleotides (ASO) to target mRNA, aptamers, ribozymes, and clustered regularly interspaced short palindromic repeats-CRISPR-associated (CRISPR/Cas) endonuclease to target proteins and DNA. Due to their diverse targeting ability and research in RNA modification and delivery systems, RNA-based formulations have emerged as suitable treatment options for many diseases. Therefore, in this article, we have summarized different RNA therapeutics, their targeting strategies, and clinical progress for various diseases as well as limitations; so that it might help researchers formulate new and advanced RNA therapeutics for various diseases. Additionally, U.S. Food and Drug Administration (USFDA)-approved RNA-based therapeutics have also been discussed.

show abstract

Synthesis of Polyols and Organic Acids by Wild-Type and Metabolically Engineered Yarrowia lipolytica Strains

Lin

Ong

et al. 2022

Synthetic Biology of Yeasts

View full text Add to dashboard Cite

Non-Conventional Yeast Species for Recombinant Protein and Metabolite Production

Cited by 5 publications

References 281 publications

Comprehensive comparison of Yarrowia lipolytica and Pichia pastoris for production of Candida antarctica lipase B

Comprehensive comparison of Yarrowia lipolytica and Pichia pastoris for production of Candida antarctica lipase B

RNA Therapeutics - Research and Clinical Advancements

Synthesis of Polyols and Organic Acids by Wild-Type and Metabolically Engineered Yarrowia lipolytica Strains

Contact Info

Product

Resources

About